The Ledger

GILD

Gilead Sciences IncHealth Careinsider_universe

Last close $125.89Jun 28, 2026

Day −1.56%

Currently held

Agent 4 — Dip Buyer (Frozen)long
8 sh @ $123.69 · stop $113.79
+$17.68 unrealized

Everything we've seen

·Jun 29, 3:49 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 3:49 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 3:49 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 3:34 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 3:34 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 3:34 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 3:18 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 3:18 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 3:18 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 3:04 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 3:04 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 3:04 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 2:48 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 2:48 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 2:48 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 2:33 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 2:33 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 2:33 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 2:18 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 2:18 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 2:18 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 2:03 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 2:03 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 2:03 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 1:48 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 1:48 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 1:48 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 1:33 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 1:33 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 1:33 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 1:18 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 1:18 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 1:18 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 1:02 PMstreamnews
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
·Jun 29, 1:02 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 1:02 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
·Jun 29, 12:47 PMstreamnews
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
·Jun 29, 12:47 PMstreamnews
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
?Jun 29, 10:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
Several factors argue against continuation of the downside move. Most importantly, a recent headline from today (12:22 UTC) notes GILD moved 3.3% HIGHER, suggesting the stock may have already seen a sharp intraday reversal pattern — a pop followed by a fade back down to -1.67% is a classic reversal/fade structure, not a clean trending move. This kind of whipsaw behavior suggests the downside momentum is not clean or conviction-driven. Additionally, macro context shows T10YIE at 2.1σ below its 24-month trend, meaning inflation expectations are suppressed — this is supportive for long-duration assets and biotech/pharma names like GILD, providing a modest macro tailwind against further downside. The dividend-focused headline also reinforces a value/income bid that could support the stock into the close. With 300 minutes remaining there is ample time, but the reversal pattern off intraday highs back through flat and into negative territory raises concern about choppy, directionless price action rather than a clean trend to fade into the close. The -1.67% move is meaningful but the context suggests it is a give-back of an earlier spike rather than fresh initiated selling. Probability of downside continuation falls below the 0.5 threshold; no position is triggered.
!Jun 29, 10:45 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
Several factors argue against continuation of the downside move. Most importantly, a recent headline from today (12:22 UTC) notes GILD moved 3.3% HIGHER, suggesting the stock may have already seen a sharp intraday reversal pattern — a pop followed by a fade back down to -1.67% is a classic reversal/fade structure, not a clean trending move. This kind of whipsaw behavior suggests the downside momentum is not clean or conviction-driven. Additionally, macro context shows T10YIE at 2.1σ below its 24-month trend, meaning inflation expectations are suppressed — this is supportive for long-duration assets and biotech/pharma names like GILD, providing a modest macro tailwind against further downside. The dividend-focused headline also reinforces a value/income bid that could support the stock into the close. With 300 minutes remaining there is ample time, but the reversal pattern off intraday highs back through flat and into negative territory raises concern about choppy, directionless price action rather than a clean trend to fade into the close. The -1.67% move is meaningful but the context suggests it is a give-back of an earlier spike rather than fresh initiated selling. Probability of downside continuation falls below the 0.5 threshold; no position is triggered.
❖Jun 29, 8:40 AMnewsvia finnhub
Gilead Sciences Inc (NASDAQ:GILD): A Sustainable Dividend Leader in the Biotechnology Sector
Gilead Sciences offers a sustainable 2.65% dividend yield with strong financial health. This article explains how to find reliable income stocks using ChartMill’s dividend, health, and profitability filters.
❖Jun 29, 8:22 AMnewsvia finnhub
Gilead (GILD) Moves 3.3% Higher: Will This Strength Last?
Gilead (GILD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
❖Jun 27, 8:07 PMnewsvia finnhub
Gilead (GILD) Wins FDA Approval for Trodelvy in TNBC
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 12 Most Profitable S&P 500 Stocks to Invest In. On June 25, 2026, the Food and Drug Administration approved Trodelvy from Gilead Sciences, Inc. (NASDAQ:GILD) for two indications in adults with triple-negative breast cancer. The first approval covers sacituzumab govitecan-hziy as a single agent for the first-line […]
❖Jun 27, 12:15 AMnewsvia finnhub
Will Trodelvy’s First-Line TNBC Approval Redefine Gilead Sciences’ (GILD) Oncology-Led Investment Narrative?
Earlier this week, Gilead Sciences received FDA approval for an expanded use of Trodelvy, authorizing it as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer, either alone in PD-(L)1–ineligible patients or in combination with Keytruda for PD-L1–positive tumors. This decision, underpinned by robust Phase 3 ASCENT-03 and ASCENT-04 data and reinforced by top-tier NCCN guideline endorsements, elevates Trodelvy’s role in breast cancer...
❖Jun 26, 11:10 PMnewsvia finnhub
Gilead Sciences (GILD) Wins First Line Trodelvy Approval In The US And Europe
FDA approved Gilead Sciences' (NasdaqGS:GILD) Trodelvy for first line treatment of metastatic triple negative breast cancer in the US. Regulators in Europe granted a similar first line approval, creating aligned indications across key markets. Decisions follow clinical data showing survival benefits for patients treated with the Trop 2 directed antibody drug conjugate. Gilead Sciences has been known largely for its antiviral portfolio, and Trodelvy adds further weight to its growing...
❖Jun 26, 10:45 AMnewsvia finnhub
Ascendis Pharma (ASND) Moves 9.9% Higher: Will This Strength Last?
Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
✓Jun 26, 10:11 AMdecisionacted
Agent 7 — Day Trader — decide: buy
GILD is up 2.71% on a concrete catalyst — Cantor Fitzgerald reiterating Overweight following positive HIV trial results, which is a credible, specific, fundamental driver. Analyst reiterations post-trial data tend to attract incremental buy-side attention through the session as the note circulates. The prior day's dip headline suggests the stock was oversold into this catalyst, which adds to the setup. Macro context is mildly supportive: T10YIE at 1.9σ below trend implies lower real rates / inflation expectations, which is generally favorable for long-duration healthcare/biotech names. With 335 minutes remaining there is ample time for continuation. No reversal signals noted. The main drag on conviction is that the move is already 2.71%, limiting the remaining distance to the +3% profit target from current levels — but from the prior close that target sits around $127.55, which is only ~$0.35 away, making a quick fill plausible. No evidence of fade or volume thinning. Probability set at 0.63 reflecting solid but not exceptional continuation setup.
❖Jun 26, 9:10 AMnewsvia finnhub
CDC Raises Its Response Level To Congo Ebola Outbreak To Level 1 Activation, Its Highest Level; Says Risk Of Ebola Spreading In The U.S. Remains Low
https://www.cdc.gov/ebola/situation-summary/index.html
❖Jun 26, 7:11 AMnewsvia finnhub
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results
Gilead Sciences Inc. (NASDAQ:GILD) ranks among the best set-it-and-forget-it stocks to buy right now. Cantor Fitzgerald restated an Overweight rating and a $155 price target for Gilead Sciences Inc. (NASDAQ:GILD) on June 9, following the company’s clinical research findings. Gilead Sciences Inc. (NASDAQ:GILD), in collaboration with Merck, revealed solid top-line results from the phase 3 […]
▢Jun 25, 8:00 PMjournal
Agent 7 — Day Trader opened long 23 @ $127.20
▣Jun 25, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 23 @ $125.57 (-$37.61)
EOD forced close — day trader never carries overnight
❖Jun 25, 6:00 PMnewsvia finnhub
Gilead Sciences (GILD) Dips More Than Broader Market: What You Should Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $123.84, denoting a -1.05% move from the preceding trading day.
❖Jun 25, 10:19 AMnewsvia finnhub
Gilead's Breast Cancer Drug Trodelvy Wins FDA Nod for Expanded Use
GILD wins FDA approval to expand Trodelvy into first-line metastatic triple-negative breast cancer, opening a broader treatment opportunity.
❖Jun 25, 7:17 AMnewsvia finnhub
Gilead's Trodelvy Expands Reach With New FDA Approval In Breast Cancer
FDA approves Gilead's Trodelvy for first-line metastatic triple-negative breast cancer, expanding use alone and with Keytruda.
❖Jun 25, 6:45 AMnewsvia finnhub
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each with Trodelvy® (sacituzumab govitecan-hziy) as First-Line Treatment of PD-L1+ (CPS ≥10) Advanced Triple-Negative Breast Cancer (TNBC)
RAHWAY, N.J., June 25, 2026--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead’s Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative br
❖Jun 25, 5:36 AMnewsvia finnhub
Is GSK Quietly Becoming An Oncology Powerhouse
GSK stock outlook: 3.46% dividend yield, 2026 core EPS growth guided at 7%â9%, and Exdensur as a new asthma growth driverâread the analysis now.
❖Jun 25, 2:54 AMnewsvia finnhub
Merck Announces FDA Approval Of KEYTRUDA And KEYTRUDA QLEX, Each In Combination With Trodelvy, For First-Line Treatment Of Breast Cancer
U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead’s
❖Jun 24, 4:29 PMnewsvia finnhub
U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
FOSTER CITY, Calif., June 24, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). Trodelvy is now approved in first-line mTNBC either as a single agent for patients who are not candidates for
❖Jun 24, 2:15 PMnewsvia finnhub
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
By Daniella Parra VERAXA Biotech AG (Nasdaq: VRXA)has expanded its R&D facility in Heidelberg, Germany, increasing laboratory space by more than 60% to support team growth and accelerate its cancer therapy programs toward clinical development, the company said. The expansion strengthens research capabilities while allowing the company to remain in Heidelberg’s leading medical oncology hub […] The post VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development a
❖Jun 24, 12:30 PMnewsvia finnhub
Gilead Sciences Receives FDA Approval For Its Trodelvy Antibody-Dug Conjugate To Treat Adult Patients With Unresectable Locally Advanced Or Metastatic Triple-Negative Breast Cancer
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate (ADC),
❖Jun 24, 11:25 AMnewsvia finnhub
Gilead Wins EC Approval to Expand Trodelvy's Label in Metastatic TNBC
Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.
❖Jun 23, 11:50 AMnewsvia finnhub
The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch.
The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.
❖Jun 23, 8:20 AMnewsvia finnhub
Should You Buy Or Sell AbbVie Stock At $230?
The drugmaker has successfully replaced its former blockbuster, but buying into that victory today means paying a steep premium for its next act.
❖Jun 23, 7:45 AMnewsvia finnhub
European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
FOSTER CITY, Calif., June 23, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease and are not candidates for PD-1 or PD-L1 inhibitor therapy. Trodelvy is the first antibody-drug conjugate (ADC
❖Jun 23, 5:52 AMnewsvia finnhub
3 S&P 500 Stocks with Exciting Potential
The S&P 500 (^GSPC) is packed with companies that have built dominant market positions, making it a core index for investors. A select few continue to innovate and expand, setting themselves up for long-term success.
❖Jun 23, 5:00 AMnewsvia finnhub
Gilead Sciences: The Market Is Underestimating Its Growth Runway
Gilead stock looks like a long-term value buy after the pullback, with HIV growth, Yeztugo sales upside, and a safe dividend. Click to read more about GILD.
❖Jun 23, 3:46 AMnewsvia finnhub
Gilead Sciences Receives European Commission's Marketing Authorization For Trodelvy As Monotherapy To Treat Adult Patients With Unresectable Or Metastatic Triple-Negative Breast Cancer
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) as monotherapy for the treatment of adult patients
❖Jun 22, 11:40 AMnewsvia finnhub
Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing
By Karen Roman Prolium Bioscience, Inc. said it dosed its first patient in Phase 1/2 study of PRO-203, a T-cell engager treatment for systemic sclerosis, following the completion of a study in 20 healthy volunteers. The company also completed the last patient and visit in a 26-week study of PRO-203 in treatment-refractory lupus nephritis patients, […] The post Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing appeared first on ExecEdge.
❖Jun 22, 9:09 AMnewsvia finnhub
Could This FDA Milestone Unlock Gilead’s (GILD) Next Big Growth Driver?
With a short percentage of shares outstanding of 2.07%, Gilead Sciences, Inc. (NASDAQ:GILD) is among the 7 Best Longevity and Anti-Aging Stocks to Buy. On June 15, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for Yeztugo 300-mg tablets as a potential once-weekly oral pre-exposure prophylaxis (PrEP) treatment for HIV prevention. […]
❖Jun 22, 7:10 AMnewsvia finnhub
Merck (MRK) Wins FDA Expansions, Posts HIV Data, And Ends Lung Cancer Trial
Merck (NYSE:MRK) received FDA approval for expanded use of KEYTRUDA and KEYTRUDA QLEX with WELIREG as adjuvant treatment in certain renal cell carcinoma patients. The FDA also granted expanded approval for CAPVAXIVE in children and adolescents at higher risk for pneumococcal disease, making it the only PCV indicated for this US group. Merck and Gilead reported positive Phase 3 data for a once weekly oral HIV treatment regimen. Separately, Merck discontinued a Phase 3 lung cancer trial...
❖Jun 19, 12:47 AMnewsvia finnhub
U.S. opens tariff probe targeting Germany’s drug pricing policies
U.S. Trade Representative Jamieson Greer said Germany's proposal to reduce spending on medicines was "a serious step backwards."
✓Jun 18, 6:21 PMdecisionacted
Agent 4 — Dip Buyer (Frozen) — decide: buy
Gilead Sciences is a large-cap, well-established biopharmaceutical company with durable cash flows from its HIV and oncology franchises, and no recent news or SEC filings in the window suggest any fundamental deterioration driving this 10% pullback. The macro context shows a compressed yield curve (T10Y2Y at 0.29, 3.5σ below trend), which is consistent with a risk-off or defensive rotation environment that could temporarily weigh on even high-quality healthcare names. Given the absence of company-specific negative catalysts, this drop appears to be macro/sector-rotation driven rather than a reflection of underlying business weakness.
?Jun 18, 6:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $63.15 cash available; close=$123.69.
!Jun 18, 6:05 PMsignal
Agent 8 — Dip Buyer (Peer-Aware) — insufficient_capital
GILD is a fundamentally sound large-cap biopharma with an established HIV/oncology franchise and consistent cash generation. The 10% pullback from the 30-day high appears macro/sector-driven rather than company-specific, as there are no negative headlines, SEC filings, or insider sales to suggest fundamental deterioration. Health Care (XLV) ranks 3rd of 11 by 30-day relative strength and shows modest outperformance vs. SPY over 30 days (+0.99pts), suggesting the sector backdrop is neutral-to-supportive, and today's broad market is risk-on (SPY +0.76%, QQQ +2.38%), which could provide near-term tailwind. With earnings 48 days away (non-imminent) and VIX at a moderate 18.44 (69th percentile, not extreme), the risk/reward for a 90-day swing is acceptable.
?Jun 18, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.52 cash available; close=$123.69.
❖Jun 18, 4:20 PMnewsvia finnhub
Dividend Champion, Contender, And Challenger Highlights: Week Of June 21
Track weekly dividend updates for Champions, Contenders & Challengers: dividend changes, upcoming ex-dividend dates, and pay dates.
❖Jun 18, 10:34 AMnewsvia finnhub
VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026
By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) reported in vitro proof-of-concept data validating its BiTAC-ADC platform for cancer therapies, with selective tumor cell killing while sparing healthy cells. The company will showcase partnering opportunities for its platform at the BIO International Convention in San Diego, California, taking place on June 22-25, 2026, it stated […] The post VERAXA Unveils Cancer Therapy Platform, Sparks Partnering Talks at BIO 2026 appeared first on ExecEdge.
❖Jun 18, 9:12 AMnewsvia finnhub
How to trade the SpaceX dip
The Investment Committee debate whether it's safe to buy the SpaceX dip. Joe Terranova, senior managing director for Virtus Investment Partners, joins CNBC's 'Halftime Report' to detail his latest portfolio moves.
❖Jun 18, 9:00 AMnewsvia finnhub
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
❖Jun 18, 7:09 AMnewsvia finnhub
Gilead Sciences (GILD): Buy, Sell, or Hold Post Q1 Earnings?
Since December 2025, Gilead Sciences has been in a holding pattern, posting a small return of 2.7% while floating around $124.73. The stock also fell short of the S&P 500’s 10.9% gain during that period.
❖Jun 18, 2:53 AMnewsvia finnhub
Abivax: Safety Signals Loom Ahead Of The NDA Submission
ABIVAX plans NDA submission for obefazimod in Q4 2026, with Crohnâs disease Phase 2b data delayed to mid-2027. Learn why ABVX stock is a strong sell.
?Jun 17, 2:20 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 1.64% today with no attributable headline catalyst, suggesting either broad sector pressure or quiet distribution. The move is meaningful but below the 2-5% threshold that would signal strong institutional conviction. Macro context shows the T10Y2Y spread is 2.3σ below trend, which is a defensive-friendly signal — GILD as a large-cap biotech/pharma defensive could see some support or at least a lack of additional selling pressure as investors rotate toward defensives in a flattening yield environment. However, that same logic could have already played out earlier and the current weakness may reflect idiosyncratic flow. With 85 minutes remaining there is sufficient time for continuation, but the modest move magnitude and the defensives-supportive macro context create competing forces. No reversal pattern or volume anomaly is identified. On balance, this is a borderline read: the momentum is modestly downward, the macro is not clearly additive to further selling, and the position has bounded risk. Assigning continuation probability at 0.50 — the weakest trigger threshold — reflecting genuine uncertainty between continued drift lower and a mean-reversion bid into close given the defensive macro backdrop.
!Jun 17, 2:20 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down 1.64% today with no attributable headline catalyst, suggesting either broad sector pressure or quiet distribution. The move is meaningful but below the 2-5% threshold that would signal strong institutional conviction. Macro context shows the T10Y2Y spread is 2.3σ below trend, which is a defensive-friendly signal — GILD as a large-cap biotech/pharma defensive could see some support or at least a lack of additional selling pressure as investors rotate toward defensives in a flattening yield environment. However, that same logic could have already played out earlier and the current weakness may reflect idiosyncratic flow. With 85 minutes remaining there is sufficient time for continuation, but the modest move magnitude and the defensives-supportive macro context create competing forces. No reversal pattern or volume anomaly is identified. On balance, this is a borderline read: the momentum is modestly downward, the macro is not clearly additive to further selling, and the position has bounded risk. Assigning continuation probability at 0.50 — the weakest trigger threshold — reflecting genuine uncertainty between continued drift lower and a mean-reversion bid into close given the defensive macro backdrop.
❖Jun 17, 2:01 PMnewsvia finnhub
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
❖Jun 17, 1:34 PMnewsvia finnhub
Gilead Sciences (GILD) Donates Remdesivir to Uganda
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Undervalued Counter Cyclical Stocks to Buy Now. On June 12, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) announced a donation of more than 2,000 vials of its intravenous antiviral therapy, remdesivir, to the Republic of Uganda to support response efforts for the current outbreak of Ebola Bundibugyo virus […]
❖Jun 17, 6:28 AMnewsvia finnhub
1 Cash-Producing Stock Worth Investigating and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
❖Jun 17, 3:41 AMnewsvia finnhub
The Zacks Analyst Blog Highlights Gilead Sciences, Merck and GSK
Gilead Sciences won FDA acceptance for a filing that could expand Yeztugo into a once-weekly oral HIV prevention option, broadening its HIV portfolio.
❖Jun 16, 2:17 PMnewsvia finnhub
FDA Accepts Gilead's Filing for Weekly Oral Yeztugo for HIV Prevention
Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.
❖Jun 16, 8:25 AMnewsvia finnhub
Stocks making the biggest moves midday: SpaceX, Lumentum, Huntsman, e.l.f. Beauty, Intel & more
Here are the companies making headlines in midday trading.
❖Jun 16, 5:05 AMnewsvia finnhub
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
?Jun 11, 3:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up 4.31% intraday, a meaningful move suggesting real institutional flow. However, several factors weigh against continuation into the close: (1) Only 30 minutes remain until the forced close, leaving very limited runway for the +3% profit target to be reached from current levels — the asymmetry of time is unfavorable. (2) No news catalyst is identifiable to explain the move, which raises the possibility this is a technical squeeze or block trade that has already fully expressed itself. (3) A 4.31% move in a large-cap defensive biotech like GILD is unusually large intraday; such moves in low-beta names often see late-session profit-taking or mean reversion as momentum traders unwind. (4) The macro context (T10Y2Y at 1.8σ below trend, bear-flattening signal) is modestly supportive of defensives like GILD in principle, but this is a mild tailwind at best and does not explain the magnitude of the move. (5) With only 30 minutes left and no fresh catalyst, the risk of a fade off the highs is elevated. The combination of extreme move magnitude for this ticker, no identifiable news, and minimal time remaining pushes the probability below the 0.5 threshold — this setup looks more like a move that has already run its course than one with continuation pressure.
!Jun 11, 3:15 PMsignalseverity 0.04
Agent 7 — Day Trader — day_trade_skipped
GILD is up 4.31% intraday, a meaningful move suggesting real institutional flow. However, several factors weigh against continuation into the close: (1) Only 30 minutes remain until the forced close, leaving very limited runway for the +3% profit target to be reached from current levels — the asymmetry of time is unfavorable. (2) No news catalyst is identifiable to explain the move, which raises the possibility this is a technical squeeze or block trade that has already fully expressed itself. (3) A 4.31% move in a large-cap defensive biotech like GILD is unusually large intraday; such moves in low-beta names often see late-session profit-taking or mean reversion as momentum traders unwind. (4) The macro context (T10Y2Y at 1.8σ below trend, bear-flattening signal) is modestly supportive of defensives like GILD in principle, but this is a mild tailwind at best and does not explain the magnitude of the move. (5) With only 30 minutes left and no fresh catalyst, the risk of a fade off the highs is elevated. The combination of extreme move magnitude for this ticker, no identifiable news, and minimal time remaining pushes the probability below the 0.5 threshold — this setup looks more like a move that has already run its course than one with continuation pressure.
?Jun 11, 9:41 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up 1.76% today, a moderate but meaningful move suggesting real buying interest. The headline from this morning frames GILD as a deep value play with pipeline progress — supportive but not a catalyst-level surprise. The macro backdrop (T10Y2Y at 0.42, 1.8σ below trend) reflects a mild flattening environment that favors defensives, and GILD as a large-cap biotech/healthcare name fits that defensive profile reasonably well. With 365 minutes remaining (essentially a full trading day still ahead), there is ample time for the move to extend — no time compression discount needed. No reversal signals are indicated. The move is not large enough to suggest exhaustion, and the sector tailwind from a bear-flattening macro environment provides modest incremental support. Overall, this is an ordinary momentum setup with no strong fade catalyst, warranting a mild lean toward continuation.
!Jun 11, 9:41 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is up 1.76% today, a moderate but meaningful move suggesting real buying interest. The headline from this morning frames GILD as a deep value play with pipeline progress — supportive but not a catalyst-level surprise. The macro backdrop (T10Y2Y at 0.42, 1.8σ below trend) reflects a mild flattening environment that favors defensives, and GILD as a large-cap biotech/healthcare name fits that defensive profile reasonably well. With 365 minutes remaining (essentially a full trading day still ahead), there is ample time for the move to extend — no time compression discount needed. No reversal signals are indicated. The move is not large enough to suggest exhaustion, and the sector tailwind from a bear-flattening macro environment provides modest incremental support. Overall, this is an ordinary momentum setup with no strong fade catalyst, warranting a mild lean toward continuation.
?Jun 11, 7:04 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $18.65 cash available; close=$121.48.
!Jun 11, 7:04 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
GILD passes the hard veto check: earnings are 55 days away (no imminent binary risk), no recent filings show fundamental deterioration, and the sector (Health Care / XLV) is actually outperforming the market significantly (+7.41pts vs SPY over 5 days, +4.33pts over 30 days), ranking 2nd of 11 sectors. Signal scoring: the drop is 11.7% (below the 15% threshold, so no mean-reversion bonus), options flow is bullish with a P/C ratio of 0.58 and call volume nearly double put volume (+1), and there is no earnings event within 30 days (+1). However, the stock is falling while its sector outperforms, suggesting an idiosyncratic issue (-1). VIX at the 79th percentile is elevated (-1), and the 10Y yield at 4.53% is a mild headwind for a defensive/value name (neutral, 0). Net signal score: +2, supporting a marginal buy. The base rate of ~55-60% for a 10%+ dip recovery is anchored, and macro headwinds (elevated VIX, broad market weakness today with QQQ -2%, SPY -1.58%) trim this modestly to ~0.52.
?Jun 11, 7:04 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
GILD is a financially sound, deep-value biotech (HIV franchise generating durable cash flows) trading at a meaningful 11.7% discount from its 30-day high, with Health Care as one of the strongest sectors right now (rank 2/11, outperforming SPY by +4.33pts over 30 days). The drop appears idiosyncratic rather than sector-driven — the stock is falling while its sector outperforms, suggesting a company-specific overhang. Options flow is modestly bullish (P/C 0.58, more calls than puts) but z-scores are unavailable, limiting confidence. The consensus EPS for the upcoming August earnings is an unusual -$7.37, which is likely a one-time charge rather than ongoing impairment, but the headline number could weigh on sentiment approaching the print.
!Jun 11, 7:04 AMsignalseverity 0.12
Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped
GILD is a financially sound, deep-value biotech (HIV franchise generating durable cash flows) trading at a meaningful 11.7% discount from its 30-day high, with Health Care as one of the strongest sectors right now (rank 2/11, outperforming SPY by +4.33pts over 30 days). The drop appears idiosyncratic rather than sector-driven — the stock is falling while its sector outperforms, suggesting a company-specific overhang. Options flow is modestly bullish (P/C 0.58, more calls than puts) but z-scores are unavailable, limiting confidence. The consensus EPS for the upcoming August earnings is an unusual -$7.37, which is likely a one-time charge rather than ongoing impairment, but the headline number could weigh on sentiment approaching the print.
❖Jun 10, 9:00 PMnewsvia finnhub
Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development
Gilead Sciences, Inc. (NASDAQ:GILD) is a deep value stock to invest in now. On June 2, Gilead Sciences, Inc. (NASDAQ:GILD) announced topline results of the Phase 3 IDEAL study for its candidate drug Livdelzi in people with primary biliary cholangitis (PBC). Study results showed that treatment with Livdelzi (seladelpar) led to significantly more patients achieving […]
?Jun 10, 8:06 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip_no_cash
Wanted to buy but only $19.92 cash available; close=$121.48.
!Jun 10, 8:06 PMsignal
Agent 4 — Dip Buyer (Frozen) — insufficient_capital
Gilead is a fundamentally sound, cash-generative biopharmaceutical company with a durable HIV franchise and growing oncology portfolio (Kite/CAR-T). The 11.7% pullback from the 30-day high appears largely driven by macro sector rotation — the flattening yield curve (T10Y2Y at 2.1σ below trend) tends to pressure defensive/healthcare names — rather than any company-specific deterioration, as no negative catalysts, guidance cuts, or adverse filings are evident in the recent news. The Cencora-Kite deal headline is a mild positive signal for CAR-T sector sentiment.
▣Jun 10, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 200 @ $1.16 (-$202.76)
Stop: premium $1.16 ≤ trailing floor $1.81 (peak $2.42 × 0.75)
▣Jun 10, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 70 @ $1.29 (-$195.68)
Stop: premium $1.29 ≤ trailing floor $1.81 (peak $2.42 × 0.75)
❖Jun 10, 2:12 PMnewsvia finnhub
Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.
✓Jun 10, 12:16 PMdecisionacted
Agent 6 — Options Momentum — decide: buy
PUT on GILD — 5-day return -5.33% with close below 20-day MA ($130.51). IV 23.9%. Sized 2 contract(s) at $2.18 premium.
?Jun 10, 12:00 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 2.39% with no attributable headline, suggesting this is likely flow-driven or sector rotation rather than a catalyst that could be faded on resolution. With 225 minutes remaining there is ample time for continuation. The macro context shows T10Y2Y at 2.1σ below trend, which is a flattening/near-inversion signal — this favors defensives like biotech/pharma on a relative basis but not necessarily a reversal catalyst for GILD specifically. The absence of news is neutral per guidance. The move is meaningful at -2.39%, suggesting real selling pressure, but is not yet extreme enough to trigger mean-reversion instincts. No clear reversal pattern is described. Overall: mild continuation bias with no strong accelerant, probability sits just above the 0.5 threshold.
!Jun 10, 12:00 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down 2.39% with no attributable headline, suggesting this is likely flow-driven or sector rotation rather than a catalyst that could be faded on resolution. With 225 minutes remaining there is ample time for continuation. The macro context shows T10Y2Y at 2.1σ below trend, which is a flattening/near-inversion signal — this favors defensives like biotech/pharma on a relative basis but not necessarily a reversal catalyst for GILD specifically. The absence of news is neutral per guidance. The move is meaningful at -2.39%, suggesting real selling pressure, but is not yet extreme enough to trigger mean-reversion instincts. No clear reversal pattern is described. Overall: mild continuation bias with no strong accelerant, probability sits just above the 0.5 threshold.
❖Jun 10, 10:05 AMnewsvia finnhub
Cencora Kite Deal Highlights CAR T Growth And Undervalued Share Price Potential
Cencora (NYSE:COR) has entered a major U.S. distribution partnership with Kite Pharma, a Gilead company. The agreement focuses on market access and distribution support for FDA approved CAR T cell therapies across U.S. treatment centers. The collaboration is aimed at easing logistical and administrative hurdles for healthcare providers using these personalized cancer treatments. Cencora comes into this Kite agreement with a mixed share price record. The stock is trading at $279.57, with...
▣Jun 9, 8:00 PMjournaltarget
Agent 6 — Options Momentum closed long 30 @ $8.39 (+$129.19)
De-risk: premium $8.39 ≥ 2.0× entry $4.08. Selling 30/100 contracts; trailing the remainder.
▢Jun 9, 8:00 PMjournal
Agent 6 — Options Momentum opened long 200 @ $2.18
❖Jun 9, 4:12 PMnewsvia finnhub
Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Gilead Sciences, Inc. (GILD) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 9, 2026 1:20 PM EDTCompany ParticipantsDaniel O'Day - Chairman...
❖Jun 9, 4:01 PMnewsvia finnhub
Lakefront Announces Initiation of €50 Million Stock Repurchase Program
Mechelen, Belgium; June 9, 2026, 22:01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced the launch of a share repurchase program (the “Program”), under which the Company may repurchase ordinary shares for an aggregate amount of up to €50 Million. Repurchases under the Program may be made no later than December 31, 2026. The Program is entered into with Morgan Stanley & Co International PLC. Any purchase of ordinary shares done in relation to thi
❖Jun 9, 3:31 PMnewsvia finnhub
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
❖Jun 9, 1:09 PMnewsvia finnhub
Gilead’s Mixed Trial News Puts HIV Progress And Oncology Risks In Focus
Gilead Sciences (NasdaqGS:GILD) and Merck reported that their once weekly oral HIV regimen, islatravir and lenacapavir, met its primary endpoint in a Phase 3 trial, showing statistically non inferior efficacy to daily standard of care. The companies also stopped a Phase 3 study combining Trodelvy and KEYTRUDA in advanced lung cancer after the treatment did not deliver a statistically significant improvement in progression free survival. These mixed trial outcomes arrive with Gilead Sciences...
?Jun 9, 11:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 2.59% intraday — a meaningful move with real institutional flow behind it. No direct GILD-specific headline is present, but the Merck HIV/lung cancer trial headline may be creating modest sector-level sentiment spillover into large-cap biopharma names. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening) favors defensives broadly, which could provide a mild cushion to GILD as a healthcare/defensive name — a slight headwind to further downside continuation. However, with 284 minutes remaining (nearly a full session still ahead), there is ample time for the move to persist or even extend if selling pressure continues. No clear reversal signal is evident. Balancing the modest macro defensive tailwind (which could fade the move) against the meaningful intraday momentum and time remaining, this reads as a marginal continuation setup. Assigning a slight edge to continuation given the magnitude of the move and time available, but not with high conviction.
!Jun 9, 11:01 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
GILD is down 2.59% intraday — a meaningful move with real institutional flow behind it. No direct GILD-specific headline is present, but the Merck HIV/lung cancer trial headline may be creating modest sector-level sentiment spillover into large-cap biopharma names. The macro context (T10Y2Y at 2.0σ below trend, bear-flattening) favors defensives broadly, which could provide a mild cushion to GILD as a healthcare/defensive name — a slight headwind to further downside continuation. However, with 284 minutes remaining (nearly a full session still ahead), there is ample time for the move to persist or even extend if selling pressure continues. No clear reversal signal is evident. Balancing the modest macro defensive tailwind (which could fade the move) against the meaningful intraday momentum and time remaining, this reads as a marginal continuation setup. Assigning a slight edge to continuation given the magnitude of the move and time available, but not with high conviction.
❖Jun 9, 10:08 AMnewsvia finnhub
Stocks Climb on an AI-Led Rebound
The S&P 500 Index ($SPX ) (SPY ) today is up +0.93%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.89%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.17%. June E-mini S&P futures (ESM26 ) are up +0.76%, and June E-mini Nasdaq futures...
❖Jun 9, 9:44 AMnewsvia finnhub
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends
?Jun 7, 1:13 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path tells a clear distributive story. The price peak at $136.22 on 2026-05-28 was immediately followed by a massive down-day volume spike of 17.5M on 2026-05-29 (close $134.43, -1.31%) — the heaviest volume in the window until today — signaling aggressive selling into the prior strength. The path then cascaded lower through 2026-06-01 ($131.10, 6.3M) and 2026-06-02 ($127.57, 8.1M), confirming down-day volume dominance as price broke well below the mid-window cluster of $129–$134. Today's bar (2026-06-05, close $129.16, volume 15.4M, z-score +2.55 vs 20d ADV of 7.1M) is the second consecutive session of anomalously high volume ($129.18 on 13.7M yesterday), yet price is essentially flat to slightly down — a classic distribution/absorption signal, NOT accumulation, because the path has arrived here via a sequence of expanding down-day volume with no sustained price recovery. Risks: This bearish read would be invalidated if the two high-volume sessions (2026-06-04 and 2026-06-05) prove to be climactic selling exhaustion rather than distribution — a decisive close back above $132–$133 on expanding up-day volume over the next 2–3 sessions would suggest the float has been absorbed. Additionally, a macro shift in the yield curve (T10Y2Y reverting above trend) could broadly re-rate Health Care defensives upward and overwhelm the technical setup.
?Jun 4, 6:04 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] The 20-day PV path tells a clear distributive story. The dominant high-volume events are all down days: May 7 (8.9M, -1.64%), May 8 (10.3M, -2.04%), and most decisively May 29 (17.5M, -1.31%), which stands as the single largest volume print in the window and accompanied a reversal from the period high of $136.22 on May 28. That May 29 bar — heaviest volume, price decline — is textbook distribution at a local top. The subsequent path from $136.22 down to $127.57 by June 2 occurred on cumulatively elevated down-day volume (17.5M + 6.3M + 8.1M = 31.9M over three sessions), while the two recovery days (June 3 at 6.2M and today June 4 at 12.1M) fail to reclaim the prior cluster range of $131–$134, and even today's elevated volume (12.1M, z-score +1.82 vs 6.9M ADV) produces only a +0.15% close at $129.18 — a stall, not a breakout. The 2-D scatter path has drifted unmistakably down-and-right: higher aggregate volume coinciding with lower prices, the SIR signature of distribution. Risks: A reclaim of the $131–$134 cluster zone on expanding up-day volume (sustained sessions above 10M+) would undermine the distributive read and suggest re-accumulation. Additionally, any broad-market or sector catalyst driving Healthcare outperformance could compress the distribution timeline and invalidate the bearish PV path.
✓Jun 4, 6:03 PMdecisionacted
Agent 6 — Options Momentum — decide: buy
PUT on GILD — 5-day return -5.17% with close below 20-day MA ($131.96). IV 24.4%. Sized 1 contract(s) at $4.08 premium.
▢Jun 3, 8:00 PMjournal
Agent 6 — Options Momentum opened long 30 @ $4.08
▢Jun 3, 8:00 PMjournal
Agent 6 — Options Momentum opened long 70 @ $4.08
?Jun 2, 9:05 AMdecisionconsidered
Agent 7 — Day Trader — analyze: fail
Claude analysis failed: Anthropic 503: {"type":"error","error":{"type":"overloaded_error","message":"API key validation is temporarily unavailable. Please retry."},"request_id":"req_011CbeUsgetZcbMgP84FUPiR"}
!Jun 2, 9:05 AMsignal
Agent 7 — Day Trader — analyze_failed
?Jun 1, 4:22 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[exhaustion] The 20-day PV path for GILD shows a stock oscillating in a $129–$136 range with consistently subdued volume (ADV ~5–6M shares) throughout May, but today's close on 2026-05-29 registers a dramatic volume spike of 17.5M — a z-score of 8.49 above the trailing 20-day mean — on a DOWN day (-1.31%) that closes at $134.43, exactly at a recent resistance cluster formed around the $134–$136 highs of 2026-05-06 ($136.30) and 2026-05-28 ($136.22). Under SIR's 2-D framework, an unprecedented volume surge at a price extreme on a down day is a classic exhaustion/distribution signal: sellers are unloading into the prior rally at high volume, with price failing to hold. The path never showed sustained up-day volume dominance — note that the strongest up days (e.g., 2026-05-22 at $134.36 on only 6.0M and 2026-05-28 at $136.22 on 5.6M) carried well below-average volume, while the heaviest volume days (2026-05-08 at 10.3M and today at 17.5M) were both DOWN days — a textbook distribution imprint on the scatter path. Risks: This bearish read would be invalidated if the next 1–3 sessions reclaim $136+ on expanding volume (≥10M), which would reframe today's spike as a shakeout and re-open a cluster_break_up scenario. Additionally, a sector-wide health care catalyst (e.g., FDA approval, earnings surprise) could absorb the distribution pressure and resume the uptrend independently of the PV structure.
?May 29, 9:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up 1.89% today with no attributable headline, suggesting this is flow-driven rather than a news catalyst. The move is meaningful but not extreme. Macro context shows the 10Y-3M spread elevated (~1.8σ above trend), which is modestly supportive of defensives like large-cap biotech/pharma — GILD fits that profile as investors may be rotating into defensive healthcare names in a yield-curve-steepening environment. No reversal signals or news-driven fade pressure are evident. With 390 minutes remaining (session effectively full), there is ample time for continuation. However, without a clear catalyst or strong sector momentum, this is a baseline momentum read. Assigning modest continuation probability above 0.5, reflecting the default lean toward momentum continuation in the absence of fade signals, tempered by the lack of confirming evidence.
!May 29, 9:16 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is up 1.89% today with no attributable headline, suggesting this is flow-driven rather than a news catalyst. The move is meaningful but not extreme. Macro context shows the 10Y-3M spread elevated (~1.8σ above trend), which is modestly supportive of defensives like large-cap biotech/pharma — GILD fits that profile as investors may be rotating into defensive healthcare names in a yield-curve-steepening environment. No reversal signals or news-driven fade pressure are evident. With 390 minutes remaining (session effectively full), there is ample time for continuation. However, without a clear catalyst or strong sector momentum, this is a baseline momentum read. Assigning modest continuation probability above 0.5, reflecting the default lean toward momentum continuation in the absence of fade signals, tempered by the lack of confirming evidence.
?May 22, 2:50 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up 2.68% intraday with no attributable headline, suggesting organic institutional flow or a sector rotation trade rather than a news spike that might fade. The macro context (T10Y3M elevated at +2.2σ) is more relevant to banks and recession-sensitive sectors than to large-cap biopharma like GILD, so it is neither a tailwind nor a meaningful headwind here. With only 55 minutes remaining until the forced close, there is limited runway for continuation — late-session momentum can persist but the time constraint compresses the expected move. No reversal signal or fade pattern is evident from the data provided. On balance, the prior for a same-direction close on a move of this magnitude is slightly above coin-flip; no strong reason to fade, but no high-conviction catalyst to push confidence higher. Assigning modest continuation probability consistent with ordinary momentum in the absence of counter-evidence.
!May 22, 2:50 PMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
GILD is up 2.68% intraday with no attributable headline, suggesting organic institutional flow or a sector rotation trade rather than a news spike that might fade. The macro context (T10Y3M elevated at +2.2σ) is more relevant to banks and recession-sensitive sectors than to large-cap biopharma like GILD, so it is neither a tailwind nor a meaningful headwind here. With only 55 minutes remaining until the forced close, there is limited runway for continuation — late-session momentum can persist but the time constraint compresses the expected move. No reversal signal or fade pattern is evident from the data provided. On balance, the prior for a same-direction close on a move of this magnitude is slightly above coin-flip; no strong reason to fade, but no high-conviction catalyst to push confidence higher. Assigning modest continuation probability consistent with ordinary momentum in the absence of counter-evidence.
?May 22, 11:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up ~2.07% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news catalyst. The move is meaningful but not extreme. Macro context shows the 10Y-3M spread at +0.89 (2.2σ above trend), which is mildly risk-on for equities broadly, though GILD as a large-cap biotech/pharma is relatively rate-insensitive and not a primary beneficiary or victim of yield curve steepening. No reversal signals or fade patterns are noted. With 230 minutes remaining until the 3:45 ET cutoff, there is ample time for the move to extend. However, without a clear catalyst or strong sector tailwind, and given the move is already ~2% (partial exhaustion of near-term upside relative to the 3% target), the continuation edge is modest. Overall, momentum bias leans slightly in favor of continuation — no meaningful fade trigger present — warranting a probability just above the action threshold.
!May 22, 11:55 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is up ~2.07% intraday with no attributable headline, suggesting institutional flow or sector rotation rather than a news catalyst. The move is meaningful but not extreme. Macro context shows the 10Y-3M spread at +0.89 (2.2σ above trend), which is mildly risk-on for equities broadly, though GILD as a large-cap biotech/pharma is relatively rate-insensitive and not a primary beneficiary or victim of yield curve steepening. No reversal signals or fade patterns are noted. With 230 minutes remaining until the 3:45 ET cutoff, there is ample time for the move to extend. However, without a clear catalyst or strong sector tailwind, and given the move is already ~2% (partial exhaustion of near-term upside relative to the 3% target), the continuation edge is modest. Overall, momentum bias leans slightly in favor of continuation — no meaningful fade trigger present — warranting a probability just above the action threshold.
?May 22, 9:41 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up 2.37% intraday with no attributable headline, suggesting this is likely driven by either sector rotation or institutional accumulation rather than a newsworthy catalyst. The move is meaningful and represents real flow conviction. However, several factors temper enthusiasm: (1) No news catalyst means the move could be fully priced in already and subject to profit-taking into the close. (2) The macro context shows T10Y3M at 2.2σ above trend — a steepening yield curve environment that primarily benefits banks/financials, not biotech/pharma names like GILD; this is neither a tailwind nor a direct headwind but doesn't provide sector support. (3) With 364 minutes remaining (well over 6 hours — this appears to be very early in the session), there is ample time for the move to continue but also ample time for a reversal or consolidation. (4) No reversal pattern is indicated yet, and the move has not been flagged as fading. Overall, the base case is modest continuation given the size of the move and remaining time, but without a catalyst or supportive macro sector backdrop, this is a low-conviction setup. Probability sits just above the 0.5 threshold — the bounded risk profile of the system justifies taking the trade.
!May 22, 9:41 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is up 2.37% intraday with no attributable headline, suggesting this is likely driven by either sector rotation or institutional accumulation rather than a newsworthy catalyst. The move is meaningful and represents real flow conviction. However, several factors temper enthusiasm: (1) No news catalyst means the move could be fully priced in already and subject to profit-taking into the close. (2) The macro context shows T10Y3M at 2.2σ above trend — a steepening yield curve environment that primarily benefits banks/financials, not biotech/pharma names like GILD; this is neither a tailwind nor a direct headwind but doesn't provide sector support. (3) With 364 minutes remaining (well over 6 hours — this appears to be very early in the session), there is ample time for the move to continue but also ample time for a reversal or consolidation. (4) No reversal pattern is indicated yet, and the move has not been flagged as fading. Overall, the base case is modest continuation given the size of the move and remaining time, but without a catalyst or supportive macro sector backdrop, this is a low-conviction setup. Probability sits just above the 0.5 threshold — the bounded risk profile of the system justifies taking the trade.

← Back to dashboard